Karyopharm announces presentation of updated phase 2 selinexor data in patients with myelofibrosis at the american society of hematology 2021 annual meeting and exposition

Newton, mass., dec. 11, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral presentation highlighting updated data from the phase 2 essential study, an investigator-sponsored study evaluating single-agent selinexor, a first-in-class, oral selective inhibitor of nuclear export (sine) compound, in patients with myelofibrosis (mf) previously treated with jak inhibition.
KPTI Ratings Summary
KPTI Quant Ranking